Patent cliffs no longer run the pharma trade. Chris Schott, who leads US diversified biopharma research at jpmorgan's Making Sense, said investor focus is pivoting to a broad innovation cycle he called the most robust in 25 years covering the group.
Schott pointed to oncology first, where he said two drugs now meaningfully extend life in pancreatic cancer and small cell lung cancer. He also cited antibody-drug conjugates and bispecifics improving care in lung cancer, plus personalized vaccines to prevent recurrence in skin cancer, and said Keytruda could be replaced in five to seven years by better therapies.
Robbie Marcus, who leads US medical device research at jpmorgan, offered the harsher counterpoint. He said medtech sits in a trough with negative revisions, pressured co-pays and, for the first time since the financial crisis, softer procedure volumes in a normally steady sector, with recovery possibly into 2027 on new products and trial data.
On AI, Schott was practical rather than hyped. He said analysis of clinical data and faster filings is creating value today because saving six or 12 months matters when patent protection lasts 15 to 18 years, but he said early-stage target discovery remains unproven and will need three to five years to judge. I think that split is right.
The concession is access. Schott said GLP-1 penetration is still high single digits in the US and about 2% internationally, with many patients paying cash, though prices fell about 20% in 2026 and seniors can now get supply at $50 a month. That affordability push now has outside confirmation, as Eli Lilly secured approval from Chinese authorities for orforglipron, making it the first maker authorized to sell an oral GLP-1 weight-loss treatment in China, per Archyde.
If you are building in health, sell time saved and cost avoided, not models.




